AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Renal Cell Carcinoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AST-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AST-001 is under development for treatment of brain tumor, lung cancer with brain metastasis, acute lymphoblastic leukemia with brain metastasis, pancreatic cancer, hepatocellular carcinoma, gastric cancer, non-small cell lung cancer, breast cancer, esophageal cancer, colon cancer, rectal cancer, renal cell carcinoma, brain stromal tumor and prostate cancer. It is administered through intravenous route.
For a complete picture of AST-001’s drug-specific PTSR and LoA scores, buy the report here.